EDENTREE ASSET MANAGEMENT Ltd Buys 103,500 Shares of Bruker Corporation $BRKR

EDENTREE ASSET MANAGEMENT Ltd raised its stake in Bruker Corporation (NASDAQ:BRKR) by 65.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 260,900 shares of the medical research company’s stock after purchasing an additional 103,500 shares during the quarter. Bruker accounts for about 3.0% of EDENTREE ASSET MANAGEMENT Ltd’s portfolio, making the stock its 11th biggest position. EDENTREE ASSET MANAGEMENT Ltd owned approximately 0.17% of Bruker worth $10,749,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Edmond DE Rothschild Holding S.A. purchased a new stake in Bruker in the 2nd quarter valued at $62,032,000. Norges Bank bought a new stake in shares of Bruker in the 2nd quarter worth $44,459,000. Sculptor Capital LP grew its stake in shares of Bruker by 51.6% in the 1st quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock worth $108,459,000 after acquiring an additional 884,423 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after purchasing an additional 758,301 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bruker by 65.9% during the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock valued at $60,688,000 after purchasing an additional 586,516 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Up 3.4%

Shares of Bruker stock opened at $46.92 on Thursday. The stock has a market capitalization of $7.13 billion, a P/E ratio of -293.25, a P/E/G ratio of 6.68 and a beta of 1.17. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.64. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. The stock’s 50-day simple moving average is $41.28 and its 200 day simple moving average is $38.19.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. During the same quarter last year, the business earned $0.60 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is currently -125.00%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Redburn Partners set a $60.00 price objective on shares of Bruker in a research report on Thursday, November 20th. Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. UBS Group lifted their price target on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. The Goldman Sachs Group started coverage on Bruker in a research report on Tuesday. They issued a “sell” rating and a $40.00 price objective on the stock. Finally, Wells Fargo & Company decreased their target price on Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $50.62.

Insiders Place Their Bets

In other news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 27.30% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.